Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Mitsubishi Tanabe Pharma Corp Amends Mid-year Consolidated Outlook for FY 2014


Wednesday, 25 Sep 2013 02:00am EDT 

Mitsubishi Tanabe Pharma Corp announced that it has reaffirmed its mid-year consolidated outlook for revenue of JPY 200,000 million, operating profit of JPY 30,000 million, ordinary profit of JPY 31,000 million, and raised its mid-year consolidated outlook for net profit from JPY 19,000 million to JPY 26,000 million, and earnings per share from JPY 33.87 to JPY 46.35, for the fiscal year ending March 2014. This is due to the extraordinary profit of JPY 11 billion according to arbitration result. 

Company Quote

1481.0
-16.0 -1.07%
10 Jul 2014